登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Adjuvant Immune Checkpoint Inhibitor Versus Observation After Neoadjuvant Immunochemotherapy and Surgery in High-Risk NSCLC
ClinicalTrials.gov 上登记的一项肺癌开放试验,由四川大学华西医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07748325,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 5
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(5 项)收起清单
18 岁 至 75 岁;性别:不限
登记记录的入选字段
Histologically or cytologically confirmed non-small cell lung cancer.
入选标准第 2 条
Pathologic lymph-node involvement;
入选标准第 5 条
Postoperative pathologic T2 or higher disease;
入选标准第 6 条
Failure to achieve a major pathologic response, defined as more than 10% residual viable tumor cells in the primary tumor;
入选标准第 7 条
High-risk histologic components, including solid, micropapillary, or adenosquamous components;
入选标准第 10 条
Women of childbearing potential must have a negative pregnancy test within 7 days before the first dose and must agree to use effective contraception during the study and for 3 months after the last dose of study treatment. Male participants with partners of childbearing potential must agree to use effective contraception during the study and for 8 weeks after the last dose.
入选标准第 23 条
Eastern Cooperative Oncology Group performance status of 0 or 1.
入选标准第 13 条
Hemoglobin of at least 90 g/L;
入选标准第 15 条
Absolute neutrophil count of at least 1.5 × 10\^9/L;
入选标准第 16 条
Platelet count of at least 75 × 10\^9/L;
入选标准第 17 条
Total bilirubin no greater than 1.5 times the upper limit of normal;
入选标准第 18 条
Serum creatinine no greater than 1.5 times the upper limit of normal or creatinine clearance of at least 60 mL/min;
入选标准第 20 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);影像与可测量病灶;试验排除的其他疾病;怀孕、哺乳与避孕。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07748325,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Male or female participants aged 18 to 75 years. Histologically or cytologically confirmed non-small cell lung cancer. Completion of 2 to 4 cycles of neoadjuvant immune checkpoint inhibitor therapy combined with chemotherapy, followed by complete (R0) surgical resection. At least one of the following protocol-defined high-risk features for postoperative recurrence: Pathologic lymph-node involvement; Postoperative pathologic T2 or higher disease; Failure to achieve a major pathologic response, defined as more than 10% residual viable tumor cells in the primary tumor; Pleural invasion; Intravascular tumor emboli; High-risk histologic components, including solid, micropapillary, or adenosquamous components; Detectable molecular residual disease. For participants with lung adenocarcinoma, absence of sensitizing EGFR mutations and ALK rearrangements. Molecular testing is not mandatory for participants with squamous cell carcinoma according to the current protocol. Eastern Cooperative Oncology Group performance status of 0 or 1. Adequate organ function within 7 days before randomization, as demonstrated by all of the following: Hemoglobin of at least 90 g/L; Absolute neutrophil count of at least 1.5 × 10\^9/L; Platelet count of at least 75 × 10\^9/L; Total bilirubin no greater than 1.5 times the upper limit of normal; Alanine aminotransferase and aspartate aminotransferase no greater than 2.5 times the upper limit of normal; Serum creatinine no greater than 1.5 times the upper limit of normal or creatinine clearance of at least 60 mL/min; Left ventricular ejection fraction of at least 50%; International normalized ratio or prothrombin time no greater than 1.5 times the upper limit of normal. Women of childbearing potential must have a negative pregnancy test within 7 days before the first dose and must agree to use effective contraception during the study and for 3 months after the last dose of study treatment. Male participants with partners of childbearing potential must agree to use effective contraception during the study and for 8 weeks after the last dose. Ability to understand the study requirements, willingness to provide written informed consent, and ability to comply with study treatment and follow-up procedures.排除标准:Exclusion Criteria:
Small cell lung cancer or non-small cell lung cancer containing a small cell carcinoma component. Incomplete resection, including R1 or R2 resection, or salvage surgery. Clinically significant malnutrition as determined by the investigator. A history of clinically significant immune-related adverse events during prior treatment, including grade 3 or higher immune-mediated pneumonitis, myocarditis, or another serious immune-related adverse event that, in the investigator's judgment, makes further immune checkpoint inhibitor therapy unsafe. Signs, symptoms, or a known history of clinically significant interstitial lung disease. Any severe or uncontrolled concurrent medical condition, including: Inadequately controlled hypertension; Grade 2 or higher myocardial ischemia, myocardial infarction, clinically significant arrhythmia, corrected QT interval of at least 480 milliseconds, or New York Heart Association class II or higher heart failure; Active or uncontrolled infection of grade 2 or higher; Decompensated liver disease, active hepatitis, or chronic viral hepatitis requiring antiviral therapy; Renal failure requiring hemodialysis or peritoneal dialysis; Known human immunodeficiency virus infection, another acquired or congenital immunodeficiency disorder, or a history of organ transplantation; Poorly controlled diabetes mellitus, defined as fasting blood glucose greater than 10 mmol/L; Urine protein of 2+ or greater with a 24-hour urinary protein level greater than 1.0 g; Clinically significant coagulation abnormalities or an increased risk of bleeding; A seizure disorder requiring treatment. A concurrent active malignancy, except for malignancies specifically permitted by the final protocol. An active autoimmune disease or another immune-mediated disease requiring systemic treatment. Long-term treatment with systemic immunosuppressive therapy or systemic corticosteroids, except for protocol-permitted physiologic replacement therapy. An active psychiatric disorder, cognitive impairment, or another condition that would prevent provision of informed consent or adherence to study treatment and follow-up. Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.
引自 ClinicalTrials.gov, NCT07748325, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07748325,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。